LYEL
Lyell Immunopharma Inc
NASDAQ: LYEL · HEALTHCARE · BIOTECHNOLOGY
$19.73
-4.22% today
Updated 2026-04-30
Market cap
$527.78M
P/E ratio
—
P/S ratio
14,660.60x
EPS (TTM)
$-16.06
Dividend yield
—
52W range
$8 – $45
Volume
0.1M
Lyell Immunopharma Inc (LYEL) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-1,024,633.00%
ROE
-87.00%
ROA
-29.80%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | $657000.00 | $-129.38M | 100.00% | -15,538.66% | -19,692.09% |
| 2020 | $7.76M | $-204.47M | 100.00% | -2,732.56% | -2,636.31% |
| 2021 | $10.65M | $-250.22M | 100.00% | -2,016.68% | -2,349.47% |
| 2022 | $84.68M | $-183.12M | 100.00% | -220.89% | -216.24% |
| 2023 | $130000.00 | $-234.63M | 100.00% | -190,006.15% | -180,486.15% |
| 2024 | $61000.00 | $-342.99M | 100.00% | -588,122.95% | -562,285.25% |
| 2025 | $36000.00 | $-274.45M | -31,952.78% | -566,038.89% | -762,355.56% |